The patients carrying the MSH6 and MLH1 variants had EC diagnosed years later than the average age of cancer development in LS patients (60 and 57 years of age, respectively) and neither of the two were carriers of any additional variants that was considered to be of significance. Here, MSH6 is linked to cancer.